Medtronic Alum Leads Restore Medical's Innovative Heart Failure Treatment Advancements
- Chris Cleary, former Medtronic VP, now leads Restore Medical to enhance heart failure treatment solutions.
- Cleary's expertise will help Restore Medical navigate the medical device market and expand its global presence.
- Restore Medical aims to improve heart failure patient outcomes with innovative, minimally invasive therapies backed by significant investors.
Restore Medical's Strategic Leadership Appointment Signals Advancements in Heart Failure Treatment
Restore Medical Ltd., a privately held medical device company based in Or-Yehuda, Israel, is making significant strides in the clinical pathway for its innovative transcatheter therapy designed to treat heart failure with reduced ejection fraction (HFrEF). The recent appointment of Chris Cleary as Chairman of the Board of Directors marks a pivotal moment for the company. Cleary, who previously served as Senior Vice President of Corporate Development at Medtronic, brings over three decades of experience in the healthcare sector, including his role in leading transformative acquisitions such as Medtronic's $50 billion acquisition of Covidien. The infusion of Cleary's strategic insight is expected to propel Restore Medical’s ambitions in addressing the pressing needs within the heart failure treatment landscape.
Under Cleary’s leadership, Restore Medical aims to solidify its clinical development efforts and expand its global reach as it prepares for critical studies involving its innovative therapy. CEO Gilad Marom expresses strong confidence in Cleary’s ability to navigate the complexities of the medical device market, particularly in pioneering solutions that address the unmet needs of heart failure patients. The focus on minimally invasive solutions aligns with a broader industry trend toward less invasive treatments that enhance patient outcomes and quality of life. As the company readies itself for the next phase of development, Cleary's expertise is expected to play a crucial role in establishing a solid clinical and commercial foundation for the therapy.
Restore Medical's commitment to improving the quality of life for millions suffering from heart failure is underscored by its backing from notable healthcare investors, including Pitango HealthTech and Peregrine Ventures, as well as support from the European Innovation Council (EIC) Fund. This robust financial and strategic support positions the company favorably as it embarks on pivotal studies that could redefine treatment options for HFrEF. With Cleary at the helm, Restore Medical is not only enhancing its clinical capabilities but is also strategically aligning itself to make a significant impact in the field of heart failure therapies.
Related Cashu News

Merit Medical Systems Launches Employee Stock Ownership Plan to Boost Engagement and Stability
Merit Medical Systems (Ticker: MMSI) recently takes a significant step in enhancing its employee engagement and ownership structure with the launch of a new Employee Stock Ownership Plan (ESOP). The c…

Brookdale Senior Living launches second season of educational podcast "The Grey Take.
Brookdale Senior Living (Ticker: BKD) launches the second season of its popular podcast, "The Grey Take," which serves as a valuable resource for families exploring senior living options. The podcast…

Molina Healthcare Gains Momentum with Increased Risk Adjustment Payments and Positive Revenue Outlook
Molina Healthcare (Ticker: MOH) is making significant strides in its revenue outlook due to recently released risk adjustment figures from the Centers for Medicare & Medicaid Services (CMS). These upd…

Align Technology Faces Antitrust Investigation by European Commission Over Competitive Practices
Align Technology Inc. (Ticker: ALGN) faces a formal antitrust investigation from the European Commission, marking a significant development in the medical devices sector. This inquiry arises from a co…

